We report a case of therapy-related acute myeloid leukemia (t-AML), M4 FAB subtype, with t(10;11)(p14;q21) chromosome abnormality developed in a patient treated for acute promyelocytic leukemia (APL) after 4 years of continuous complete remission (CCR). Two distinct forms of t-AML have been described: the classical type and the second type. Our case has many characteristics in common with the second type of t-AML such as: exposure to topoisomerase II active agents (idarubicin (IDA), mitoxantrone (MITOX), etoposide (VP16)), M4 FAB subtype, a latency period of 39 months and absence of a preleukemic phase. However, it differs in the chromosome 11 breakpoint (hand 921 instead of q23) and absence of ALL-1 (Hrx, MLL, Htrx) gene involvement. This can represent the second observation of t-AML occurring after treatment for APL.
THERAPY-RELATED ACUTE MYELOMONOCYTIC LEUKEMIA FOLLOWING SUCCESSFUL TREATMENT FOR ACUTE PROMYELOCYTIC LEUKEMIA / E., Todisco; Testi, Anna Maria; Avvisati, Giuseppe; M. L., Moleti; M., Cedrone; Cimino, Giuseppe; F., Mancini; Amadori, Sergio; F., Mandelli. - In: LEUKEMIA. - ISSN 0887-6924. - 9:9(1995), pp. 1583-1585.
THERAPY-RELATED ACUTE MYELOMONOCYTIC LEUKEMIA FOLLOWING SUCCESSFUL TREATMENT FOR ACUTE PROMYELOCYTIC LEUKEMIA
TESTI, Anna Maria;AVVISATI, Giuseppe;CIMINO, Giuseppe;AMADORI, Sergio;
1995
Abstract
We report a case of therapy-related acute myeloid leukemia (t-AML), M4 FAB subtype, with t(10;11)(p14;q21) chromosome abnormality developed in a patient treated for acute promyelocytic leukemia (APL) after 4 years of continuous complete remission (CCR). Two distinct forms of t-AML have been described: the classical type and the second type. Our case has many characteristics in common with the second type of t-AML such as: exposure to topoisomerase II active agents (idarubicin (IDA), mitoxantrone (MITOX), etoposide (VP16)), M4 FAB subtype, a latency period of 39 months and absence of a preleukemic phase. However, it differs in the chromosome 11 breakpoint (hand 921 instead of q23) and absence of ALL-1 (Hrx, MLL, Htrx) gene involvement. This can represent the second observation of t-AML occurring after treatment for APL.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
